Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

een convened to offer

advice about the prospective analysis of the ENHANCE trial. (Announced

Nov. 19, 2007)

-- Reported on new study results that demonstrated that asenapine was more

effective than placebo and well tolerated in treating patients with

acute schizophrenia. (Announced Dec. 17, 2007)

-- Announced with Centocor, Inc., revision of a 1998 distribution

agreement regarding the development, commercialization and distribution

of both REMICADE (infliximab) and golimumab. (Announced Dec. 21, 2007)

-- Received priority review status from FDA for the company's New Drug

Application for sugammadex, an agent specifically designed to reverse

the effects of certain muscle relaxants used in surgery. Also announced

filing of an NDA with the Japanese Ministry of Health, Labor and

Welfare. (Announced Jan. 2, 2008, and Jan. 17, 2008, respectively)

-- Merck/Schering-Plough Pharmaceuticals announced the primary endpoint

and other results of the ENHANCE trial. Merck/Schering-Plough has

submitted an abstract on the ENHANCE trial for presentation at the

American College of Cardiology meeting, which will be held in March

2008. (Announced Jan. 14, 2008)

-- Reported top-line results of the IDEAL study, showing that sustained

virologic response was similar for the two leading combination

therapies for hepatitis C, and that fewer patients treated with both

PEGINTRON regimens relapsed after the end of treatment compared to

those receiving Pegasys and Copegus. (Announced Jan. 14, 2008)

-- Announced that Schering-Plough Chairman/CEO Fred Hassan intends to make

an open market purchase of $2 million of Schering-Plough Common Shares

with personal funds. (Announced Jan. 18, 2008)

-- With Merck, issued a release strongly objecting to mischaracterizations

of
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... , , BRISBANE, Calif., Sept. 17 ... it will be collaborating with National Jewish Health(R)( )investigators in ... may play a role in idiopathic pulmonary fibrosis (IPF). InterMune ... from patients who participated in the Company,s Phase 3 clinical trials ...
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... SAN MARINO, Calif., Sept. 16 Dr. M. Karen ... (Pink Sheets: VRAL), will address the 11th Annual SoCalBio Investor ... Custom Peptides on Chronic Inflammation," will take place mid-morning on ... The Loews Santa Monica Beach Hotel in Santa Monica, California. ...
Cached Biology Technology:InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Viral Genetics' Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 2
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... life can persist in a cold, dark world. A ... that examined waters and sediments from a shallow lake ... extreme environment supports microbial ecosystems. , The National ... has implications for life in other extreme environments, both ... are published in the current edition of the science ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Nature journal Leukemia suggests blocking part of ... leukemia resist treatment can increase the effectiveness of chemotherapy ... Medical Center report that their experimental combination treatment strategy ... was particularly effective at stopping a stubborn leukemia ...
... August 8, 2013 Research and ... addition of the "Fingerprint Biometrics - Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This report ... in US$ Thousands by the following Product ...
... world full of hungry predators, prey animals must be constantly ... challenge when it comes to defending themselves. "One of ... they can,t run away," says John Orrock, a zoology professor ... necessarily hide, so what can you do? Some plants make ...
Cached Biology News:Study suggests way to fight therapy resistant leukemia by blocking DNA repair 2Study suggests way to fight therapy resistant leukemia by blocking DNA repair 3Fingerprint Biometrics: Automated FIS, and Non-AFIS - Global Strategic Business Report - 2013 2Eavesdropping plants prepare to be attacked 2
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Request Info...
Biology Products: